{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["HPLC", "erlotinib", "metabolism inhibition", "microsomes", "resveratrol"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37143385", "DateCompleted": {"Year": "2023", "Month": "09", "Day": "11"}, "DateRevised": {"Year": "2023", "Month": "09", "Day": "11"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "05", "Day": "16"}], "Language": ["eng"], "ELocationID": ["10.1111/fcp.12914"], "Journal": {"ISSN": "1472-8206", "JournalIssue": {"Volume": "37", "Issue": "5", "PubDate": {"Year": "2023", "Month": "Oct"}}, "Title": "Fundamental & clinical pharmacology", "ISOAbbreviation": "Fundam Clin Pharmacol"}, "ArticleTitle": "Rapid high performance liquid chromatography method for erlotinib quantification in vitro: Application to study the effect of resveratrol on metabolism and cellular uptake of erlotinib.", "Pagination": {"StartPage": "983", "EndPage": "993", "MedlinePgn": "983-993"}, "Abstract": {"AbstractText": ["Erlotinib is a selective epidermal growth factor receptor inhibitor that is used for the treatment of non-small cell lung cancer and pancreatic cancer. Its metabolism is mainly mediated by cytochrome P450 3A (CYP 3A). Resveratrol, a natural compound found in many plants and supplements, is known to inhibit CYP3A enzyme, therefore, it may act as an inhibitor for the metabolism of erlotinib.", "Development of a rapid high performance liquid chromatography with photodiode array detection (HPLC-PDA) method for the quantification of erlotinib in liver microsomes and cancer cells and its application to study resveratrol effect on metabolism and cellular uptake of erlotinib.", "HPLC-PDA was used to develop an efficient bioanalytical method with a 2.5-min runtime preceded by a simple protein precipitation step. The method was validated according to the European Medicines Agency guidelines. Erlotinib metabolic stability and resveratrol effect on erlotinib metabolite formation were evaluated in rat liver microsomes. Furthermore, the method was used to measure the intracellular concentrations of erlotinib in cancer colorectal cells and investigating resveratrol effect on the cellular uptake of erlotinib.", "A rapid HPLC-PDA method was developed and validated for the first time to address potential drug interaction of erlotinib with resveratrol. Resveratrol was a strong inhibitor of erlotinib metabolism in vitro with IC<sub>50</sub> \u2009=\u20094.03\u2009\u03bcM. Resveratrol, however, had no effect on erlotinib cellular uptake after 1\u00a0h incubation in human colorectal cancer cells.", "The study suggests that resveratrol may produce a potential herb-drug interaction with erlotinib at the metabolism level and should be investigated in patients in the clinic."], "CopyrightInformation": "\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et de Th\u00e9rapeutique. Published by John Wiley & Sons Ltd."}, "AuthorList": [{"Identifier": ["0000-0003-0211-1866"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan."}], "LastName": "Zayed", "ForeName": "Aref", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan."}], "LastName": "Al Hroot", "ForeName": "Jomana", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Conservation Science, Queen Rania Faculty of Tourism and Heritage, The Hashemite University, Al-Zarqa, Jordan."}], "LastName": "Mayyas", "ForeName": "Abdulraouf", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan."}], "LastName": "Al-Husein", "ForeName": "Belal", "Initials": "B"}], "GrantList": [{"GrantID": "20210010", "Agency": "Deanship of Scientific Research, Jordan University of Science and Technology, Irbid", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Fundam Clin Pharmacol", "NlmUniqueID": "8710411", "ISSNLinking": "0767-3981"}, "ChemicalList": [{"RegistryNumber": "DA87705X9K", "NameOfSubstance": "Erlotinib Hydrochloride"}, {"RegistryNumber": "Q369O8926L", "NameOfSubstance": "Resveratrol"}, {"RegistryNumber": "EC 1.14.14.1", "NameOfSubstance": "Cytochrome P-450 CYP3A"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["pharmacology", "metabolism", "therapeutic use"], "DescriptorName": "Erlotinib Hydrochloride"}, {"QualifierName": [], "DescriptorName": "Chromatography, High Pressure Liquid"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Resveratrol"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Carcinoma, Non-Small-Cell Lung"}, {"QualifierName": ["metabolism"], "DescriptorName": "Lung Neoplasms"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cytochrome P-450 CYP3A"}, {"QualifierName": ["metabolism"], "DescriptorName": "Microsomes, Liver"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Iyer R, Bharthuar A. A review of erlotinib an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor. Expert Opin Pharmacother. 2010;11(2):311-320. doi:10.1517/14656560903551283"}, {"Citation": "Maher HM, Alzoman NZ, Shehata SM, Abahussain AO. UPLC-ESI-MS/MS study of the effect of green tea extract on the oral bioavailability of erlotinib and lapatinib in rats: potential risk of pharmacokinetic interaction. J Chromatogr B. 2017;1049-1050:30-40. doi:10.1016/j.jchromb.2017.02.029"}, {"Citation": "Meyerhardt JA, Zhu AX, Enzinger PC, et al. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol. 2006;24(12):1892-1897. doi:10.1200/JCO.2005.05.3728"}, {"Citation": "Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19(3):183-232. doi:10.1016/1040-8428(94)00144-I"}, {"Citation": "Fujino S, Enokibori T, Tezuka N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer Part A. 1996;32(12):2070-2074. doi:10.1016/S0959-8049(96)00243-2"}, {"Citation": "Van Sanden S, Murton M, Bobrowska A, et al. Prevalence of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer in Europe: a pragmatic literature review and meta-analysis. Target Oncol. 2022;17(2):153-166. doi:10.1007/s11523-022-00868-z"}, {"Citation": "Ling J, Johnson KA, Miao Z, et al. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos. 2006;34(3):420-426. doi:10.1124/dmd.105.007765"}, {"Citation": "Rakhit A, Pantze MP, Fettner S, et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP\u2122) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol. 2008;64(1):31-41. doi:10.1007/s00228-007-0396-z"}, {"Citation": "Shaikh AS, Thomas AB, Chitlange SS. Herb-drug interaction studies of herbs used in treatment of cardiovascular disorders-a narrative review of preclinical and clinical studies. Phyther Res. 2020;34(5):1008-1026. doi:10.1002/ptr.6585"}, {"Citation": "Rashrash M, Schommer JC, Brown LM. Prevalence and predictors of herbal medicine use among adults in the United States. J Patient Exp. 2017;4(3):108-113. doi:10.1177/2374373517706612"}, {"Citation": "Dy GK, Bekele L, Hanson LJ, et al. Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol. 2004;22(23):4758-4763. doi:10.1200/JCO.2004.03.121"}, {"Citation": "Gianchecchi E, Fierabracci A. Insights on the effects of resveratrol and some of its derivatives in cancer and autoimmunity: a molecule with a dual activity. Antioxidants. 2020;9(2):1-16. doi:10.3390/antiox9020091"}, {"Citation": "Pan J, Shen J, Si W, et al. Resveratrol promotes MICA/B expression and natural killer cell lysis of breast cancer cells by suppressing c-Myc/miR-17 pathway. Oncotarget. 2017;8(39):65743-65758. doi:10.18632/oncotarget.19445"}, {"Citation": "Athar M, Back JH, Tang X, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol. 2007;224(3):274-283. doi:10.1016/j.taap.2006.12.025"}, {"Citation": "Zhou JH, Cheng HY, Yu ZQ, He DW, Pan Z, Yang DT. Resveratrol induces apoptosis in pancreatic cancer cells. Chin Med J (Engl). 2011;124(11):1695-1699. doi:10.3760/cma.j.issn.0366-6999.2011.11.017"}, {"Citation": "Bozorgi A, Haghighi Z, Khazaei MR, Bozorgi M, Khazaei M. The anti-cancer effect of chitosan/resveratrol polymeric nanocomplex against triple-negative breast cancer; an in vitro assessment. IET Nanobiotechnol. 2022;17(2):1-12. doi:10.1049/nbt2.12108"}, {"Citation": "Xiao Q, Zhu W, Feng W, et al. A review of resveratrol as a potent chemoprotective and synergistic agent in cancer chemotherapy. Front Pharmacol. 2019;9(JAN):1-10, 1534. doi:10.3389/fphar.2018.01534"}, {"Citation": "Nie P, Hu W, Zhang T, Yang Y, Hou B, Zou Z. Synergistic induction of erlotinib-mediated apoptosis by resveratrol in human non-small-cell lung cancer cells by down-regulating survivin and up-regulating PUMA. Cell Physiol Biochem. 2015;35(6):2255-2271. doi:10.1159/000374030"}, {"Citation": "Piver B, Berthou F, Dreano Y, Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett. 2001;125(1-3):83-91. doi:10.1016/S0378-4274(01)00418-0"}, {"Citation": "Hong SP, Choi DH, Choi JS. Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats. Cardiovasc Ther. 2008;26(4):269-275. doi:10.1111/j.1755-5922.2008.00060.x"}, {"Citation": "Wen J, Bao SS, Zhang BW, et al. Inhibitory effect of resveratrol on the pharmacokinetic of ibrutinib by UPLC-MS/MS. Drug Dev Ind Pharm. 2019;45(1):27-31. doi:10.1080/03639045.2018.1514044"}, {"Citation": "Bedada SK, Yellu NR, Neerati P. Effect of resveratrol treatment on the pharmacokinetics of diclofenac in healthy human volunteers. Phyther Res. 2016;30(3):397-401. doi:10.1002/ptr.5539"}, {"Citation": "Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007;13(12):3731-3737. doi:10.1158/1078-0432.CCR-07-0088"}, {"Citation": "Qin X, Lu J, Wang P, Xu P, Liu M, Wang X. Cytochrome P450 3A selectively affects the pharmacokinetic interaction between erlotinib and docetaxel in rats. Biochem Pharmacol. 2017;143:129-139. doi:10.1016/j.bcp.2017.07.013"}, {"Citation": "van Dyk M, Rowland A. Physiologically-based pharmacokinetic modeling as an approach to evaluate the effect of covariates and drug-drug interactions on variability in epidermal growth factor receptor kinase inhibitor exposure. Transl Cancer Res. 2017;6(Suppl 10):S1600-S1612. doi:10.21037/tcr.2017.10.16"}, {"Citation": "European Medicines Agency, Guideline on bioanalytical method validation, Ref. Number EMEA/CHMP/EWP/192217/2009."}, {"Citation": "Kielkopf CL, Bauer W, Urbatsch IL. Bradford assay for determining protein concentration. Cold Spring Harb Protoc. 2020;2020(4):136-138. doi:10.1101/pdb.prot102269"}, {"Citation": "Astellas Pharm Global Development Inc. Tarceva\u00ae (erlotinib) [package insert]. US. Food and Drug Administration. Accessed May 7, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-743_Tarceva_PharmR.PDF"}, {"Citation": "McNaney CA, Drexler DM, Hnatyshyn SY, et al. An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. Assay Drug Dev Technol. 2008;6(1):121-129. doi:10.1089/adt.2007.103"}, {"Citation": "Pecic S, Zeki AA, Xu X, et al. Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability. Prostaglandins Other Lipid Mediat. 2018;136:90-95. doi:10.1016/j.prostaglandins.2018.02.004"}, {"Citation": "S\u0142oczy\u0144ska K, Gunia-Krzy\u017cak A, Koczurkiewicz P, et al. Metabolic stability and its role in the discovery of new chemical entities. Acta Pharm. 2019;69(3):345-361. doi:10.2478/acph-2019-0024"}, {"Citation": "Xu ZY, Li JL. Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. Onco Targets Ther. 2019;12:5467-5484. doi:10.2147/OTT.S194870"}, {"Citation": "Kletzl H, Zwanziger E, Kirkpatrick C, Luedin E. Effect of ciprofloxacin on the systemic exposure to erlotinib. J Clin Oncol. 2008;26(15_suppl):19047. doi:10.1200/jco.2008.26.15_suppl.19047"}, {"Citation": "I. O. P. I. and Genentech. Tarceva prescribing information. 2010. Genentech Inc. [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf"}, {"Citation": "Howells LM, Berry DP, Elliott PJ, et al. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res. 2011;4(9):1419-1425. doi:10.1158/1940-6207.CAPR-11-0148"}, {"Citation": "Detampel P, Beck M, Kr\u00e4henb\u00fchl S, Huwyler J. Drug interaction potential of resveratrol. Drug Metab Rev. 2012;44(3):253-265. doi:10.3109/03602532.2012.700715"}, {"Citation": "Williams LD, Burdock GA, Edwards JA, Beck M, Bausch J. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol. 2009;47(9):2170-2182. doi:10.1016/j.fct.2009.06.002"}, {"Citation": "Mesange P, Bouygues A, Ferrand N, et al. Combinations of bevacizumab and erlotinib show activity in colorectal cancer independent of ras status. Clin Cancer Res. 2018;24(11):2548-2558. doi:10.1158/1078-0432.CCR-17-3187"}, {"Citation": "Petit-Jean E, Buclin T, Guidi M, et al. Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature. Ther Drug Monit. 2015;37(1):2-21. doi:10.1097/FTD.0000000000000097"}, {"Citation": "Honeywell R, Yarzadah K, Giovannetti E, et al. Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(15-16):1059-1068. doi:10.1016/j.jchromb.2010.03.010"}, {"Citation": "Marchetti S, de Vries NA, Buckle T, et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008;7(8):2280-2287. doi:10.1158/1535-7163.MCT-07-2250"}, {"Citation": "Bedada SK, Yellu NR, Neerati P. Effect of resveratrol on the pharmacokinetics of fexofenadine in rats: involvement of P-glycoprotein inhibition. Pharmacol Rep. 2016;68(2):338-343. doi:10.1016/j.pharep.2015.08.018"}], "ReferenceList": [], "Title": "REFERENCES"}], "History": [{"Year": "2023", "Month": "4", "Day": "9"}, {"Year": "2022", "Month": "11", "Day": "25"}, {"Year": "2023", "Month": "4", "Day": "30"}, {"Year": "2023", "Month": "9", "Day": "11", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "5", "Day": "5", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "5", "Day": "5", "Hour": "3", "Minute": "42"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37143385", "10.1111/fcp.12914"]}}], "PubmedBookArticle": []}